an update on cyp17 inhibition in prostate cancer
Published 5 years ago • 470 plays • Length 36:22Download video MP4
Download video MP3
Similar videos
-
5:59
apalutamide in combination with abiraterone acetate, docetaxel and prednisone for mcrpc
-
10:00
results from acis trial of apalutamide abiraterone/prednisone in patients with chemo-naive mcrpc
-
1:52
treatment sequencing in mcrpc: cabazitaxel vs. abiraterone or enzalutamide
-
3:47
parp inhibitors for metastatic hormone sensitive prostate cancer
-
1:50
a phase i trial of apalutamide plus abiraterone acetate, docetaxel, and prednisone in mcrpc
-
4:12
ocuu-crpc trial: enzalutamide vs. flutamide for crpc after bicalutamide
-
2:59
niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer
-
1:53
dr. nicholas vogelzang discusses sequencing abiraterone and enzalutamide
-
1:06
imaagen: phase 2 trial of abiraterone acetate for advanced prostate cancer
-
1:23
casodex® (bicalutamide)- carcinoma of the prostate
-
5:07
neoadjuvant abiraterone acetate plus leuprolide acetate in localised high-risk prostate cancer
-
1:20
panther: apalutamide abiraterone in black and white mcrpc patients
-
2:13
head-to-head: tolerability of enzalutamide vs. abiraterone acetate for metastatic crpc
-
8:14
casodex tab (bicalutamide) : common uses in prostate cancer management
-
4:21
phase ii results of olaparib and abiraterone for mcrpc
-
1:07
dr. penson on treatment selection in metastatic hormone-sensitive prostate cancer
-
4:46
quality of life and new therapeutic options for metastatic castration-resistant prostate cancer
-
4:25
chemotherapy versus abiraterone acetate in mhspca
-
1:24
luparp: 177lu-psma-617 and parp inhibitor combination for prostate cancer